Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: Qualified Opinion who wrote (3773)	12/27/2002 4:17:23 PM
From: Qualified Opinion	Respond to of 10345

< Competition ? > Pfizer Receives Approval for Anti-Migraine Medicine Relpax(R) Friday December 27, 12:26 pm ET NEW YORK, Dec. 27 /PRNewswire-FirstCall/ -- Pfizer Inc said today that it has received approval from the U.S. Food and Drug Administration to market Relpax (eletriptan hydrobromide) for the acute treatment of migraine. ADVERTISEMENT Relpax is the newest product in the class of anti-migraine medicines known as triptans. In clinical trials involving more than 9,000 patients and more than 70,000 migraine attacks, Relpax was shown to relieve migraine pain and associated symptoms including nausea and sensitivity to light and sound. This relief can help patients return to their daily activities. An estimated 28 million Americans -- one in five women and one in 15 men -- experience migraines. Most migraine sufferers are between the ages of 30 and 50, the most productive years of life. For many, migraine is a chronic and debilitating condition that affects the ability to function both at work and at home. Migraine costs American employers about $13 billion annually because of missed workdays and lost productivity due to impaired work function. "With its effectiveness in treating pain and other symptoms of migraine, Relpax is an important new treatment option for patients that can help them get back to their lives," said Dr. Joseph Feczko, Pfizer's executive vice president of Global Research and Development and president of Worldwide Development. Discovered and developed by Pfizer, Relpax is a selective 5-hydroxytryptamine 1B/1D (5-HT1B/1D) receptor agonist that acts at serotonin 5HT1B receptors on intracranial blood vessels and 5HT1D receptors on sensory nerve endings to relieve the pain and associated symptoms of a migraine attack. Relpax was shown to be effective at doses of 20 mg, 40 mg and 80 mg. The maximum recommended single dose of Relpax is 40 mg. The most common side effects reported in clinical trials included fatigue, somnolence, nausea, and dizziness. The common adverse events seen with Relpax are similar to adverse events reported with triptans as a class. Relpax should not be used by patients with severe hepatic impairment, or those older than 65 years or younger than 18. Relpax tablets should not be used within at least 72 hours with potent CYP3A4 inhibitors. Eletriptan (Relpax) has been approved for use in the acute treatment of migraine in 51 countries and has been introduced in 17 countries including Mexico, Italy, France and Japan. Pfizer Neuroscience is committed to pioneering innovative therapies for neurological and psychiatric disorders. Pfizer's experience in the areas of depression, anxiety, schizophrenia, Alzheimer's disease and epilepsy has helped bring leading medicines to market for the treatment of these disorders. Neurologic and psychiatric disorders represent an important priority in Pfizer's $5.2 billion development effort, with more than 20 percent of the research and development budget allocated to the development of more effective neuroscience medicines for disorders such as mood and anxiety disorders, migraine, neuropathic pain, fibromyalgia, epilepsy and smoking cessation. Pfizer Inc discovers, develops, manufactures and markets leading prescription medicines, for humans and animals, and many of the world's best-known consumer products. Full prescribing information for Relpax is available upon request. Link:http://biz.yahoo.com/prnews/021227/nyf026_2.html